Advertisement

Picture Enterprise Lithuania Life Sciences Baltics 2021 Digital 650x95px
Organisation › Details

Catalym GmbH

CatalYm is a biopharmaceutical company developing novel cancer immunotherapies targeting Growth-and-Differentiation Factor 15 (GDF-15). Apart from its established role in cachexia, GDF-15 has been associated with immunosuppression in tissues and tumors and a rapidly growing body of literature supports the concept that GDF-15 is a major T cell repellent. CatalYm aims to neutralize GDF-15 to turn “cold” tumors “hot” and thereby substantially improving the efficacy of established immunotherapy such as anti-PD1/-PD-L1 checkpoint inhibitors. The company’s lead product candidate CTL-002, a neutralizing GDF-15 antibody, is set to enter clinical development in H2 2020. The Company was founded with initial investments from Forbion and BGV in 2016 as a spin-off from the Julius-Maximilians-University of Würzburg based on the innovative research work of Prof. Dr. Joerg Wischhusen. CatalYm is led by a seasoned senior executive team with substantial IO drug development as well as deal making experience and backed by international venture capital investors. CatalYm also received financial support from the EIF via the EIB-EIF Co-investment Facility, backed by the European Union through the European Fund for Strategic Investments (EFSI). *

 

Period Start 2016-08-03 established
  Predecessor University of Würzburg
Products Industry cancer immunotherapy (immuno-oncology, I-O)
  Industry 2 CTL-002 (GDF-15 antibody, Catalym)
Persons Person L’Huillier, Phil (Catalym 202105– CEO before MSD Europe + Cancer Research Technology + BioFocus Discovery)
  Person 2 Burger, Anne (MedVenture Partners 2002– Director + Breath Therapeutics 201609– CFO + Curetis 201007–2012 CFO)
     
Region Region München (Munich)
  Country Germany
  Street 19 Am Klopferspitz
  City 82152 Martinsried
  Tel +49-89-2000-664-40
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Catalym GmbH. (11/10/20). "Press Release: Catalym Raises EUR50 Million to Advance GDF-15 Antibody into Clinical Trials for Checkpoint-inhibitor Refractory Patients". Munich.
     
   
Record changed: 2021-05-11

Advertisement

Picture Enterprise Lithuania Life Sciences Baltics 2021 Digital 650x95px

More documents for Catalym GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Demy-Colton BioFuture 2021 NYC C Lee Hood Speaking 650x300px




» top